Takeda Pharmaceutical Co Ltd
Close on Nov 20, 2026Market cap $75.03BP/E –Yield –
Takeda Pharmaceutical Adjusted EBITDA (Last Twelve Months / LTM): 1,540.30 JPY billion in Q2 FY27, up 13.8% from a year earlier. That is the highest of the 16 quarters on record here.
Where the Q2 FY27 figure comes from
“|| Adjusted EBITDA (LTM) *5 | 1,540.3 | Net increase (decrease) in short-term loans and commercial papers | (341.8) | —”
Source: SEC EDGAR Filing (exhibit991_102926.htm) ↗
Reported in Form 6-K Exhibit 99.1 Quarterly Financial Appendix.
quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Adjusted EBITDA (Last Twelve Months / LTM) | Year on year | Source |
|---|---|---|---|---|
| Q2 FY27CQ3 2026 | Sep 30, 2026 | 1,540.30 | +13.8% | SEC EDGAR Filing (exhibit991_102926.htm) ↗ |
| Q1 FY27CQ2 2026 | Jun 30, 2026 | 1,503.80 | +9.6% | SEC EDGAR Filing (exhibit991_073026.htm) ↗ |
| Q4 FY26CQ1 2026 | Mar 31, 2026 | 1,457.20 | +1.1% | SEC EDGAR Filing (exhibit991_051326.htm) ↗ |
| Q3 FY26CQ4 2025 | Dec 31, 2025 | 1,404.50 | -4.5% | SEC EDGAR Filing (exhibit991_012926.htm) ↗ |
| Q2 FY26CQ3 2025 | Sep 30, 2025 | 1,353.90 | -7.2% | SEC EDGAR Filing (exhibit991_103025.htm) ↗ |
| Q1 FY26CQ2 2025 | Jun 30, 2025 | 1,372.40 | -0.7% | SEC EDGAR Filing (exhibit991_073025.htm) ↗ |
| Q4 FY25CQ1 2025 | Mar 31, 2025 | 1,441.00 | +9.2% | SEC EDGAR Filing (exhibit991_050825.htm) ↗ |
| Q3 FY25CQ4 2024 | Dec 31, 2024 | 1,471.00 | +8.2% | SEC EDGAR Filing (exhibit991_013025.htm) ↗ |
| Q2 FY25CQ3 2024 | Sep 30, 2024 | 1,459.20 | +3.8% | SEC EDGAR Filing (exhibit991_103124.htm) ↗ |
| Q1 FY25CQ2 2024 | Jun 30, 2024 | 1,382.40 | -3.9% | SEC EDGAR Filing (exhibit991_073124.htm) ↗ |
| Q4 FY24CQ1 2024 | Mar 31, 2024 | 1,319.90 | -7.2% | SEC EDGAR Filing (exhibit991_050924.htm) ↗ |
| Q3 FY24CQ4 2023 | Dec 31, 2023 | 1,358.90 | – | SEC EDGAR Filing (exhibit991_020124.htm) ↗ |
| Q2 FY24CQ3 2023 | Sep 30, 2023 | 1,406.20 | – | SEC EDGAR Filing (exhibit991_102623.htm) ↗ |
| Q1 FY24CQ2 2023 | Jun 30, 2023 | 1,438.80 | – | SEC EDGAR Filing (exhibit991_072723.htm) ↗ |
| Q4 FY23CQ1 2023 | Mar 31, 2023 | 1,421.80 | +21.7% | SEC EDGAR Filing (exhibit991_051123.htm) ↗ |
| Q4 FY22CQ1 2022 | Mar 31, 2022 | 1,168.00 | – | SEC EDGAR Filing (exhibit991_051123.htm) ↗ |
Cite this data
StockData. (2026). Takeda Pharmaceutical Adjusted EBITDA (Last Twelve Months / LTM), quarterly Q4 FY22–Q2 FY27 [Data set]. Compiled from Takeda Pharmaceutical SEC filings and investor materials. https://stockdatahq.com/stocks/tak/kpis/sec-adj-ebitda-ltm
See every metric in the Takeda Pharmaceutical KPI table. Data updated Nov 10, 2026.
See a number that looks wrong?